To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

January 16, 2018

Today's Rundown

Featured Story

In conversation with: Sarepta CEO Doug Ingram

After the dust had settled on another J.P. Morgan Healthcare Conference, we caught up with Doug Ingram, the relatively new chief at rare disease biotech Sarepta, and discussed how he aims to remove the term “controversial” that we bio reporters keeping slapping in front of the company’s name.

Top Stories

Eiger writes off ubenimex in PAH after total flop in phase 2

Eiger BioPharmaceuticals is ready to stop development of ubenimex in pulmonary arterial hypertension (PAH). The biotech indicated ubenimex failed to find a hint of efficacy after a phase 2 trial in the indication.

AveXis steps up gene therapy pursuit of Biogen’s SMA pathfinder

AveXis is expanding trials of its gene therapy for children with spinal muscular atrophy (SMA) with a series of new trials as it plays catch-up with Biogen and Ionis, which claimed the first approval for an SMA drug.

[Sponsored] Contract Execution Timelines: An Important Factor in Site Selection

The impact of protracted contracting timelines can be felt throughout the study start-up process. Coupling predictive enrollment analytics with contract execution timelines of a site decreases time to Last Patient First Visit by up to 25%.

Pherecydes raises cash to trial anti-infective phage therapies

Pherecydes has raised money to take bacteriophage-based anti-infectives into clinical trials. The €8.7 million ($10.6 million) series B will support studies targeting two bacterial infections and the creation of a drug manufacturing unit.

Pfizer puts Foundation Medicine at the center of its cancer companion diagnostic strategy

Pfizer has struck a broad cancer companion diagnostic deal with Foundation Medicine. The alliance will see Foundation Medicine use pan-cancer test FoundationOne CDx as a companion diagnostic for Pfizer drugs.

Google, Sequoia back Oxford universal flu vaccine developer Vaccitech

On its way to developing a universal flu vaccine, University of Oxford spinout Vaccitech has raised £20 million in series A financing, backed by Google parent company Alphabet’s venture capital arm GV, Sequoia China and Oxford Sciences Innovation.

Enrollment Showcase

Online Graduate Programs Designed for Your Career

Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more.

Resources

[Whitepaper] Streamline your mAb Intact Protein Characterization: Download App Note

This Agilent intact protein analysis includes:

[Marketplace] Asia-Pacific Compliance Training for Life Sciences Professionals

Don’t miss this educational program trusted by multi-national companies as part of their employee’s compliance training. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating in the Asia-Pacific region. Visit event page for session topics.

[Whitepaper] Is Your In-House Strategy Ready For The Uncertainties Of Biologic Drug Development?

Download Patheon’s whitepaper to discover two main areas where a drug developer can face significant obstacles during biologics development and how by evaluating these capabilities, it can answer the critical question of whether its in-house strategy is ready for these uncertainties.

[Webinar] How to Prevent, Identify, and Implement a Clinical Trial Rescue

What do you do when timelines are missed, data is dirty, and everyone is pointing fingers? Join this webinar to learn how to prevent, identify, and implement a successful clinical trial rescue.

[Whitepaper] Key to regulatory transformation is unified RIM

Expanding into new markets places a spotlight on inefficient processes.

[Whitepaper] Best Practices for Managing Regulatory Processes 

Regulatory leaders share challenges and best practices from a lack of standardization, manual processes, and fragmented systems.

[Whitepaper] Choosing the Right Solution: Improving the Site Feasibility Process

Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals.

[Whitepaper] 5 Steps to Managing Quality Globally

Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives.

[Whitepaper] How Do Sponsors Ensure Quality in Global Clinical Trials?

Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives.

[Webinar] Validating a 7 Day Membrane Filtration Sterility Test using Celsis®

Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols.

[Infographic] Evolution of Flexible Commercial Biologics Manufacturing

Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility.

[eBook] Developing Site-specifically Modified ADCs: Using a Chemoenzymatic Approach

Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology.

[Article] Optimizing titer and use of a specific enzyme for generating a fully processed antibody

Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing.

[Webinar] Within-Subject Clinical Trials: Intro to New Methods & Stat. Models

In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods.

Events

.